Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dow Jones Industrial Average ETF (DIA) vs DexCom, Inc. (DXCM) Price & Performance

Dow Jones Industrial Average ETFTrade
DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

Dow Jones Industrial Average ETF vs DexCom, Inc. — how do they compare? Dow Jones Industrial Average ETF trades at $526.38, while DexCom, Inc. trades at $74.91 (market cap $28.60B). The key difference: Dow Jones Industrial Average ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.

DIADXCM
52-Week High
$530.02$89.53
52-Week Low
$435.72$54.84
Market Cap
$28.60B
Sector
Health
Enterprise Value
$27.57B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dow Jones Industrial Average ETF

DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $524.40, down 0.27% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks the Dow Jones Industrial Average's 30 blue-chip stocks, providing diversified exposure to large-cap U.S. equities. Recent news highlights its 52-week high achievement and inclusion of Alphabet, boosting its tech weighting. Dividend distributions continue with scheduled payouts through mid-2026.

Outlook remains positive given the Dow's 8% year-to-date gain and DIA's 10-year average annual return of 13.3%. Key opportunities include broad market exposure and dividend income, while risks involve Fed policy shifts and concentration in cyclical sectors. Analyst sentiment is favorable due to the ETF's low-cost structure and historical performance.

DexCom, Inc.

DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.

DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dow Jones Industrial Average ETF

The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on DIA

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM